“There is a movement underway, and it has been growing for a long time.”
PROUD to be a part of the movement. #WIC#SheForShe#HeForShe 👩🏼⚕️🙌🏼 https://t.co/6EBY4DySSq
ACC/AHA & 9 other leading medical associations released an updated clinical guideline for managing #dyslipidemia. About 1 in 4 US adults has high LDL-C, raising risk of heart attack & stroke.
Get the details in #JACC: https://t.co/pT3H1NCzyZ
#ClinicalGuidelines#cvLipids#ASCVD
We knew clopidogrel was better a long time ago. And without a higher bleeding risk. Read CAPRIE. Was just really expensive at the time. Now it's my SAPT of choice for most pts when I'm stopping DAPT. Not novel.
In the large ROLLING STONE registry (1,005 pts, 23 Italian centers) comparing #IVL vs #atherectomy in calcified lesions, procedural success was similar, but IVL showed significantly ⬇️MACE & CV death at 30 days & 12 months. https://t.co/olu95gh1AW #JACCINT@veronica_lio
@DrMarthaGulati Everything you just said 💯. Now we will spend another few minutes of our already minuscule amount of time with patients trying to undo these non scientific statements.
This is what you get from Trump. Violence against people caring for your children, only because of their color and spanish accent. Witnesses say she has a work permit. Teaches kids spanish at an immersion school.
A very nice study from #EACTS2025. I will cover today on the This Week in Cardiology podcast. Once again, guidelines are too aggressive. And biased toward action.
🚨 NEW: Netflix secretly recorded an interview with Dr. Jane Goodall in March, set to air only after her death.
In it, she says she wishes Trump and Elon Musk could be blasted into space… and closes with:
“Don’t lose hope.”
Now that’s a final message.
My #Cardiology paper of the year: Daily Step Count in @JACCJournals
The optimal steps to ⬇️ CVD events is NOT THAT HIGH! Totally achievable!
Its easy to get discouraged by the marathoners, bodybuilders, etc. Sure that's great, but not necessary. Do enough, the benefits follow
Agent ISR- YES!! Nearly three-quarters of the patients had intravascular image guided ISR PCI….and the outcomes were very good. Now that’s progress! Let’s next hope for rapid FDA approval of Agent coupled with wide adoption of intravascular imaging for all ISR cases.
Safety of Continuing #MRA Treatment in Patients with #HFrEF and Severe Kidney Disease
In this study from the Swedish Heart Failure Registry of 33,942 HFrEF patients (EF < 40%):
📍51% received MRA, with varying rates across #eGFR levels.
📍Higher eGFR & severe HF features correlated with more MRA use.
📍MRA use didn't increase risk of renal events, all-cause ☠️, or 🏥 across eGFR levels, including severe #CKD
https://t.co/FdR5K5pNZV @EJHFEiC@HFA_President@MarcoMetra@ESC_Journals
🌟Pub alert! While #preeclampsia (PE)⬆️CVD risk, how do we identify those ♀️whose arteries are already on a disease path? Led by @paquin_amelie ,we showed that PE ♀️who remain HTNsive have much worse arterial health, and may be prioritized for #CVPrev ➡️https://t.co/oFGmb69459
Don’t miss this joint AHA/ACC webinar! Achieving gender equity in cardiology requires collaboration with our male allies! Join us to discuss what #HeForShe means in cardiology !
#AHAWIC#ACCWIC@gina_lundberg@PamTaubMD@RBP0612
Big news #ESC2023 and @NEJM
In a placebo-controlled randomized trial of people with obesity + heart failure (with preserved ejection fraction). semaglutide (Wegovy) markedly improved symptoms, exercise time, reduced inflammatory markers (and weight loss)
https://t.co/3pKdKB7cJH
Late breaking at #ESCCongress: In patients with heart failure with preserved ejection fraction and obesity, semaglutide (2.4 mg) led to greater reductions in symptoms and physical limitations and greater improvements in exercise function than placebo. Full STEP-HFpEF trial: